SecBot SecBot
8-K ·Filed May 12, 2026

OLMA

Olema Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-218142
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on pipeline catalysts, not quarterly financials. Key events to watch: ASCO presentation of OP-3136 data (late May 2026) and top-line OPERA-01 Phase 3 data (fall 2026). The $505M cash position funds operations through these milestones. No revenue or earnings guidance was provided.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Olema Pharmaceuticals reported Q1 2026 financial results, with a net loss of $53.1M (vs $30.4M in Q1 2025) driven by increased R&D spending on late-stage trials. The company ended the quarter with $505.3M in cash and highlighted upcoming catalysts: top-line Phase 3 OPERA-01 data expected this fall and initial Phase 1 data for OP-3136 at ASCO. As a pre-revenue clinical-stage biotech, the widening loss was expected and the cash runway supports operations through key data readouts.

Key Financial Metrics

EPS
−$0.50
est −$0.54 · +7.4%
Rating
in line

Key Facts

  • Net loss for Q1 2026 was $53.1M, compared to $30.4M in Q1 2025
  • Cash, cash equivalents, and marketable securities were $505.3M as of March 31, 2026
  • GAAP R&D expenses were $49.2M in Q1 2026 vs $30.6M in Q1 2025
  • GAAP G&A expenses were $8.8M in Q1 2026 vs $4.2M in Q1 2025
  • Top-line data from Phase 3 OPERA-01 trial of palazestrant expected in fall 2026
  • Initial Phase 1 clinical data for OP-3136 to be presented at ASCO in May 2026
  • No revenue reported; company is a clinical-stage biopharmaceutical firm

Financial Impact

Net loss increased by $22.7M YoY to $53.1M; cash burn rate increased as R&D spending rose 61% to $49.2M

net_lossr_and_d_expensescash_position

Risk Factors

  • Phase 3 OPERA-01 trial failure would be a significant negative catalyst
  • Cash burn rate is accelerating as R&D spending increases
  • No approved products or revenue; fully dependent on clinical trial success

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-218142
Document: olma-ex99_1.htm0001193125-26-218142
Document: 0001193125-26-218142-index-headers.html0001193125-26-218142
Document: 0001193125-26-218142-index.html0001193125-26-218142
Document: 0001193125-26-218142.txt0001193125-26-218142
8-K Data (Synthetic)0001193125-26-218142

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026